USPTO Declares Stem Cell Patent Interference

Law360, New York (December 14, 2009, 3:30 PM EST) -- The U.S. Patent and Trademark Office has declared an interference between a patent application by Geron Corp. and a patent owned by Novocell Inc. related to stem cell technology, Geron said Monday.

The patent at the center of the dispute, U.S. Patent Number 7,510,876, was issued in March 2009 to San Diego-based stem cell engineering company Novocell Inc. It covers technology that differentiates human embryonic stem cells into the precursors of various endoderm cell types, including pancreatic islet cells that can be used to treat diabetes....
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.